Department of Medicine, Englewood Hospital and Medical Center, Englewood, NJ, USA.
J Clin Rheumatol. 2012 Sep;18(6):301-3. doi: 10.1097/RHU.0b013e3182685515.
Tumor necrosis factor inhibitors (TNFi) have established efficacy in psoriasis and psoriatic arthritis; however, there are concerns regarding the risk of lymphoma with their use. Although current data suggest that this risk is not increased with TNFi treatment, there are no data on the risk of recurrence of previously treated lymphoma under TNFi therapy. Herein, we describe a 46-year-old man with recurrent non-Hodgkin lymphoma whose refractory psoriatic arthritis was effectively treated for 5.5 years with the TNFi etanercept, initiated just 7 months after achieving lymphoma remission, without recurrence of non-Hodgkin lymphoma. However, he subsequently died 6.5 years later of pancreatic adenocarcinoma.
肿瘤坏死因子抑制剂（TNFi）在银屑病和银屑病关节炎中已被证实有效；然而，人们对其使用相关的淋巴瘤风险存在担忧。尽管目前的数据表明 TNFi 治疗并未增加这种风险，但对于 TNFi 治疗下先前治疗的淋巴瘤的复发风险尚无数据。在此，我们描述了一例 46 岁男性，他患有复发性非霍奇金淋巴瘤，其难治性银屑病关节炎在接受 TNFi 依那西普治疗后有效，在淋巴瘤缓解后仅 7 个月即开始治疗，5.5 年内未复发非霍奇金淋巴瘤。然而，他随后在 6.5 年后因胰腺腺癌去世。
